Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A recent study led by OUCRU researchers highlighted the factors associated with the number of visits to one tertiary public hospital (Hospital for Tropical Diseases in Ho Chi Minh City) that serves as the referral clinic for two-thirds of Vietnam for Hepatitis C virus treatment.

Healthcare provider talking with a patient

Accessing healthcare is often hindered by expensive and multi-visit treatments. The investigation was focused on the factors influencing healthcare-seeking behaviour for asymptomatic, chronic Hepatitis C (HCV) virus infection, necessitating costly treatment at an urban tertiary care referral hospital in Vietnam.

A secondary analysis of hospital data for patients attending the Hospital for Tropical Diseases in Ho Chi Minh City, Vietnam between 2017 and 2020 specifically for HCV infection treatment was conducted. This study published in the BMC Infectious Diseases shows that both structural and individual factors influence the number of visits for HCV treatment. To achieve the global strategy of eliminating HCV, the Vietnamese government is required to address both systemic and personal barriers to healthcare, especially for women.

Read the full story on the Centre for Tropical Medicine and Global Health website. 

Similar stories

KEMRI renews collaboration with Wellcome Trust and University of Oxford

The Kenya Medical Research Institute (KEMRI) has signed a seven-year Memorandum of Agreement with Wellcome Trust, a UK charitable organization, and the University of Oxford, on Wednesday 27 November 2024, at the KEMRI Headquarters, Nairobi. Under this collaboration, Wellcome has awarded GBP 91 million (KES 15 billion) to support research over the next 7 years.